Key insights
- Moderna director sold shares to cover tax liabilities after restricted stock units vested. Despite strong recent returns and a Q1 revenue beat driven by international COVID-19 sales, InvestingPro suggests the stock is overvalued. Analyst price target revisions are mixed, with RBC Capital raising its target while BofA Securities remains Underperform. The director's sale, while planned, adds a slightly negative signal.
Hussain Abbas, a director at Moderna, Inc. (NASDAQ:MRNA), sold 5,682 shares of the company’s common stock on May 1, 2026, for a total value of $264,951. The shares were sold at a price of $46.63 per share, slightly below the current stock price of $47.32. The biotech company has delivered strong returns recently, with shares up 64% over the past year and 91% over the last six months, according to InvestingPro data. Despite this momentum, InvestingPro analysis suggests the stock appears overvalued relative to its Fair Value estimate.
This transaction followed the conversion of 16,233 restricted stock units into common stock on April 30, 2026. The restricted stock units vested in full on that date, converting on a one-for-one basis into common stock. The sale of shares by Mr. Abbas was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on September 5, 2025. According to the filing, the sale was made to generate proceeds to cover the tax liability incident to the vesting of the restricted stock units.
Following these transactions, Mr. Abbas directly holds 12,066 shares of Moderna common stock.
In other recent news, Moderna Inc. reported its first-quarter 2026 earnings, showcasing a notable revenue beat against expectations. The company achieved COVID-19 revenue of $352 million, surpassing the consensus estimate of $232 million, with significant contributions from international markets. Additionally, Moderna’s total revenue for the quarter reached $389 million, exceeding BofA Securities’ estimate of $305 million and the broader consensus of $259 million. This revenue performance was largely driven by international COVID-19 sales and partnership deliveries.
In response to these results, RBC Capital raised its price target for Moderna to $38, maintaining a Sector Perform rating. Similarly, BofA Securities increased its price target to $32 while continuing to rate the stock as Underperform. Despite a larger-than-expected loss per share, the earnings report has sparked investor optimism regarding Moderna’s strategic growth and product pipeline. These developments highlight the company’s ongoing efforts in expanding its international market presence and partnerships.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.